Updated options for liver-limited metastatic colorectal cancer

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Liver metastases from colorectal cancer (CRC) are common in patients presenting with an initial diagnosis of metastatic disease or at the time of recurrence.Without treatment, patients with metastatic disease have a poor prognosis. Surgical resection of the metastases might provide long-term benefit.; however, the size, number, or location of the metastases can limit the ability to perform a resection. The use of chemotherapy, both systemic and via hepatic artery infusion, in patients undergoing surgery for liver metastases from CRC has augmented the long-term survival benefits and even the cure obtained in some patients with surgery. Chemotherapy might also convert a portion of patients with initially unre- sectable liver metastases to resectable. A growing body of literature is helping to define the role of chemotherapy for potentially resectable liver metastases and for initially unresectable liver metastases. The introduction of newer agents such as oxaliplatin and irinotecan, and targeted agents such as cetuximab and bevacizumab, has led to meaningful improvements in response rates and survival over those previously achieved with 5-fluorouracil. Further trials are needed to refine the use of chemotherapy and targeted agents in the management of patients with liver metastases.

Original languageEnglish (US)
JournalClinical Colorectal Cancer
Volume7
Issue numberSUPPL. 2
DOIs
StatePublished - 2008

Fingerprint

Colorectal Neoplasms
Neoplasm Metastasis
Liver
Drug Therapy
irinotecan
oxaliplatin
Hepatic Artery
Fluorouracil
Survival Rate
Recurrence
Survival

Keywords

  • Conversion therapy
  • Epidermal growth factor inhibitors
  • Hepatic artery infusion
  • Liver metastases
  • Perioperative chemotherapy

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology

Cite this

Updated options for liver-limited metastatic colorectal cancer. / Alberts, Steven Robert.

In: Clinical Colorectal Cancer, Vol. 7, No. SUPPL. 2, 2008.

Research output: Contribution to journalArticle

@article{a49e2db387044c5e8cdcd6ed5742e914,
title = "Updated options for liver-limited metastatic colorectal cancer",
abstract = "Liver metastases from colorectal cancer (CRC) are common in patients presenting with an initial diagnosis of metastatic disease or at the time of recurrence.Without treatment, patients with metastatic disease have a poor prognosis. Surgical resection of the metastases might provide long-term benefit.; however, the size, number, or location of the metastases can limit the ability to perform a resection. The use of chemotherapy, both systemic and via hepatic artery infusion, in patients undergoing surgery for liver metastases from CRC has augmented the long-term survival benefits and even the cure obtained in some patients with surgery. Chemotherapy might also convert a portion of patients with initially unre- sectable liver metastases to resectable. A growing body of literature is helping to define the role of chemotherapy for potentially resectable liver metastases and for initially unresectable liver metastases. The introduction of newer agents such as oxaliplatin and irinotecan, and targeted agents such as cetuximab and bevacizumab, has led to meaningful improvements in response rates and survival over those previously achieved with 5-fluorouracil. Further trials are needed to refine the use of chemotherapy and targeted agents in the management of patients with liver metastases.",
keywords = "Conversion therapy, Epidermal growth factor inhibitors, Hepatic artery infusion, Liver metastases, Perioperative chemotherapy",
author = "Alberts, {Steven Robert}",
year = "2008",
doi = "10.3816/CCC.2008.s.009",
language = "English (US)",
volume = "7",
journal = "Clinical Colorectal Cancer",
issn = "1533-0028",
publisher = "Elsevier",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Updated options for liver-limited metastatic colorectal cancer

AU - Alberts, Steven Robert

PY - 2008

Y1 - 2008

N2 - Liver metastases from colorectal cancer (CRC) are common in patients presenting with an initial diagnosis of metastatic disease or at the time of recurrence.Without treatment, patients with metastatic disease have a poor prognosis. Surgical resection of the metastases might provide long-term benefit.; however, the size, number, or location of the metastases can limit the ability to perform a resection. The use of chemotherapy, both systemic and via hepatic artery infusion, in patients undergoing surgery for liver metastases from CRC has augmented the long-term survival benefits and even the cure obtained in some patients with surgery. Chemotherapy might also convert a portion of patients with initially unre- sectable liver metastases to resectable. A growing body of literature is helping to define the role of chemotherapy for potentially resectable liver metastases and for initially unresectable liver metastases. The introduction of newer agents such as oxaliplatin and irinotecan, and targeted agents such as cetuximab and bevacizumab, has led to meaningful improvements in response rates and survival over those previously achieved with 5-fluorouracil. Further trials are needed to refine the use of chemotherapy and targeted agents in the management of patients with liver metastases.

AB - Liver metastases from colorectal cancer (CRC) are common in patients presenting with an initial diagnosis of metastatic disease or at the time of recurrence.Without treatment, patients with metastatic disease have a poor prognosis. Surgical resection of the metastases might provide long-term benefit.; however, the size, number, or location of the metastases can limit the ability to perform a resection. The use of chemotherapy, both systemic and via hepatic artery infusion, in patients undergoing surgery for liver metastases from CRC has augmented the long-term survival benefits and even the cure obtained in some patients with surgery. Chemotherapy might also convert a portion of patients with initially unre- sectable liver metastases to resectable. A growing body of literature is helping to define the role of chemotherapy for potentially resectable liver metastases and for initially unresectable liver metastases. The introduction of newer agents such as oxaliplatin and irinotecan, and targeted agents such as cetuximab and bevacizumab, has led to meaningful improvements in response rates and survival over those previously achieved with 5-fluorouracil. Further trials are needed to refine the use of chemotherapy and targeted agents in the management of patients with liver metastases.

KW - Conversion therapy

KW - Epidermal growth factor inhibitors

KW - Hepatic artery infusion

KW - Liver metastases

KW - Perioperative chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=58949104198&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58949104198&partnerID=8YFLogxK

U2 - 10.3816/CCC.2008.s.009

DO - 10.3816/CCC.2008.s.009

M3 - Article

C2 - 19064408

AN - SCOPUS:58949104198

VL - 7

JO - Clinical Colorectal Cancer

JF - Clinical Colorectal Cancer

SN - 1533-0028

IS - SUPPL. 2

ER -